Literature DB >> 29579547

Transfection of bone marrow derived cells with immunoregulatory proteins.

Julia N Khantakova1, Alexander N Silkov1, Valeriy P Tereshchenko1, Elena V Gavrilova2, Rinat A Maksyutov2, Sergey V Sennikov3.   

Abstract

In vitro electroporation gene transfer was first performed in 1982. Today, this technology has become one of the major vehicles for non-viral transfection of cells. All non-viral transfections, such as calcium phosphate precipitation, lipofection, and magnetic transfection, have been shown to achieve a transfection efficiency of up to 70% in commonly used cell lines, but not in primary cells. Here we describe the use of electroporation to transfect primary mouse bone marrow-derived cells, such as macrophages (Mφ) and dendritic cells (DCs) with high efficiencies (45%-72%) and minimal cell death. The transfection efficiencies and cell death varied depending on the culture duration of the DCs and Mφ. Moreover, the electroporation efficiency was increased when conditioning medium was used for culturing the cells. Furthermore, we demonstrated that measuring the plasmid-encoded secreted proteins is a highly sensitive method for determining the transfection efficiency. In summary, electroporation with plasmid vectors is an efficient method for producing DCs and Mφ with transient expression of immunoregulatory proteins.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dendritic cells; Electroporation; Interleukin-10; Macrophage; sTNFRI

Mesh:

Substances:

Year:  2018        PMID: 29579547     DOI: 10.1016/j.cyto.2018.03.028

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  1 in total

1.  Dendritic Cells Transfected with MHC Antigenic Determinants of CBA Mice Induce Antigen-Specific Tolerance in C57Bl/6 Mice.

Authors:  Sergey V Sennikov; Valeriy P Tereshchenko; Vasiliy V Kurilin; Julia A Shevchenko; Julia A Lopatnikova; Alexander N Silkov; Amir Z Maksyutov; Maria S Kuznetsova; Nadezda Y Knauer; Aleksey S Bulygin; Julia N Khantakova
Journal:  J Immunol Res       Date:  2020-09-04       Impact factor: 4.818

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.